ENDURA THC-HS

ENDURA THC-HS Suppositories represent CBD International Clinic’s most advanced cannabinoid delivery system, engineered for patients requiring rapid, reliable, and sustained symptom relief where traditional oral or inhaled methods fall short.

Formulated using THC-hemisuccinate (THC-HS), a water-soluble prodrug of Δ9-THC, the ENDURA line is designed to optimize systemic absorption via rectal administration bypassing many of the limitations associated with oral cannabinoids, or standard rectal cannabis suppositories, including poor bioavailability and with oral, first-pass liver metabolism.

Core Innovation

The ENDURA platform incorporates a precision absorption delivery matrix that enhances mucosal uptake and stabilizes cannabinoid release.

• Improved Bioavailability: Internal formulation design aims to significantly increase systemic THC exposure compared to conventional oral formats(Note: Replace “70% more bioavailable” with “designed to significantly improve bioavailability” unless backed by clinical data.)
• Bypasses First-Pass Metabolism: Enables more predictable plasma levels of active THC
• Sustained Duration: Effects may persist 4–8 hours, supporting longer relief windows

Clinical Positioning

ENDURA THC-HS suppositories are particularly suited for:

• Severe and chronic pain management
• Cancer-related symptoms and palliative care
• Neurological conditions (e.g., tremors, spasticity)
• Patients with nausea, vomiting, or inability to ingest orally
• Sleep disruption and severe discomfort states

This delivery format allows patients to achieve therapeutic effects without pulmonary exposure and with reduced psychoactive variability compared to edibles.

Why THC-HS Matters

Unlike standard THC oils or edibles:

• THC-HS is water-soluble, enhancing absorption across rectal mucosa
• It is rapidly hydrolyzed in plasma, releasing active THC after absorption
• Provides more consistent pharmacokinetics, especially in compromised patients

Differentiation in the Market

CBD International Clinic is currently among the only providers offering a THC-HS–based suppository platform at scale, positioning ENDURA as:

• A high-efficacy alternative to traditional cannabis formats
• A medical-focused delivery system, not recreational
• A precision-dosed therapeutic option for complex conditions

Formulation & Quality

• Produced under controlled conditions using pharmaceutical-grade inputs
• Standardized dosing formats for predictable outcomes
• Designed for patient comfort and consistent administration